Welcome to our dedicated page for Definium Therapeutics news (Ticker: DFTX), a resource for investors and traders seeking the latest updates and insights on Definium Therapeutics stock.
Definium Therapeutics, Inc. (Nasdaq: DFTX) is a New York-based biopharmaceutical company focused on psychedelic-inspired therapeutics for psychiatric and neurological disorders. The Definium Therapeutics news feed on Stock Titan aggregates company announcements and media releases so readers can follow how its clinical and corporate story develops over time.
According to the company, its late-stage pipeline centers on DT120 orally disintegrating tablet (ODT), which is in Phase 3 trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD). News items may include updates on the Voyage and Panorama studies in GAD, the Emerge and Ascend studies in MDD, and other milestones related to DT120 ODT, which the company reports has received FDA Breakthrough Therapy Designation for GAD.
Definium also reports an early-stage program, DT402, in a Phase 2a study for adults with autism spectrum disorder (ASD). Coverage can feature progress in this study, as well as broader pipeline developments and commentary on the company’s efforts to advance psychedelic-inspired medicines in psychiatry.
In addition to clinical updates, Definium Therapeutics news may highlight corporate developments such as its rebranding from Mind Medicine (MindMed) Inc., changes to its Nasdaq ticker symbol DFTX, and participation in industry conferences. Investors, analysts, and observers can use this page to review historical press releases and announcements that explain how Definium frames its mission to forge a new era of psychiatry and its plans to translate evidence into impact for patients.
Definium Therapeutics (NASDAQ:DFTX) published a retrospective study in the Journal of Mood and Anxiety Disorders showing diagnosed generalized anxiety disorder (GAD) rose from 5.4% in 2020 to 6.6% in 2023, with a three‑year cumulative prevalence of 10.3% among U.S. adults.
The analysis found annual incidence of 2.1–2.3%, a female predominance (67%), and high comorbidity with major depressive disorder, underscoring unmet treatment needs and calls for improved access and new therapies.
Definium Therapeutics (NASDAQ: DFTX) issued inducement option grants to three newly hired non-executive employees totaling 55,580 common share options with grant dates of March 16, 2026 and March 30, 2026. Exercise price equals the closing share price on each grant date.
The options vest over four years (25% at year one, then monthly over three years) and were approved by the compensation committee on March 13, 2026 under NASDAQ Rule 5635(c)(4). Grants were made outside the company's equity incentive plans as material inducements to employment.
Definium Therapeutics (NASDAQ: DFTX) will host an Investor & Analyst Day in New York on April 22, 2026 from 10 AM–12 PM EDT with presentations and live Q&A from company executives and external key opinion leaders.
Topics include Phase 3 DT120 ODT (lysergide tartrate) clinical program for GAD and MDD, expectations for anticipated 2026 topline data readouts, and market opportunity. In-person attendance is limited; virtual live and archived webcast available on the company investor site for at least 30 days.
Definium Therapeutics (NASDAQ:DFTX) announced inducement equity grants to four newly hired non-executive employees with grant dates of Feb 24, 2026, Feb 27, 2026 and Mar 9, 2026. Grants include 134,540 stock options and 34,500 performance share units (PSUs) at target.
Options use the closing price on each grant date, vest over four years (25% after one year, then monthly), and PSUs vest after three years with 0%–200% payout based on performance. Grants were approved Feb 23, 2026 under NASDAQ Rule 5635(c)(4) and were issued outside the company's equity plans.
Definium Therapeutics (NASDAQ:DFTX) reported full-year 2025 results and program updates on February 26, 2026. Key highlights include $411.6 million in cash and investments as of December 31, 2025 and a completed $259 million equity financing in 4Q 2025.
Clinical milestones: Emerge (Phase 3 MDD) fully enrolled (149 patients) with topline late 2Q 2026; Voyage (Phase 3 GAD) ~80% enrolled, topline early 3Q 2026; Panorama on track for 2H 2026. DT120 Phase 2b results published in JAMA and DT120 has FDA Breakthrough Designation for GAD.
Definium Therapeutics (NASDAQ: DFTX) announced that management will participate in multiple investor conferences in March 2026, including TD Cowen (Mar 2), Jefferies Biotech on the Beach (Mar 10), Leerink Global Healthcare (Mar 11) and Stifel Virtual CNS Forum (Mar 17).
Live webcasts and replays will be available on the company’s investor relations website for up to 90 days following each event.
Definium Therapeutics (NASDAQ: DFTX) will report full year 2025 financial results via a live webcast on Thursday, February 26, 2026 at 4:30 p.m. EST.
The company said the webcast will include a discussion of recent business updates; registration and analyst participation links are provided and a replay will be archived on the Investor Relations website for at least 30 days.
Definium Therapeutics (NASDAQ:DFTX) announced inducement option grants to two newly hired non-executive employees totaling 28,640 common share options with an effective grant date of February 2, 2026. The exercise price equals the closing share price on each grant date.
Vesting is over four years: 25% at the first anniversary and the remaining 75% in substantially equal monthly installments over the following three years, subject to continued employment. The grants were approved by the Compensation Committee on January 29, 2026, granted outside the company’s equity incentive plans in accordance with Nasdaq Rule 5635(c)(4).
Definium Therapeutics (NASDAQ:DFTX) appointed Roger Adsett to its Board of Directors effective January 29, 2026.
Adsett brings more than two decades of commercial and launch experience, including leadership at Insmed, and will support Definium as it approaches three anticipated Phase 3 readouts in 2026.
Definium Therapeutics (NASDAQ:DFTX) announced inducement option grants to three newly hired non-executive employees totaling 88,850 options with effective grant dates of January 12 and January 26, 2025. The exercise price equals the closing price on each grant date. The options vest over four years with 25% on the first anniversary and the remaining 75% monthly over the next three years, subject to continued employment. The grants were approved by the company's Compensation Committee on January 8, 2026 under NASDAQ Rule 5635(c)(4) and were issued outside of Definium's equity incentive plans as material inducements to employment.